Bone mineral density in adult patients with pyruvate kinase deficiency on long-term mitapivat treatment
Hanny Al‐Samkari(Harvard University), Eduard J. van Beers(Utrecht University), Jaime Morales(Agios Pharmaceuticals (United States)), Rachael F. Grace(Dana-Farber/Boston Children's Cancer and Blood Disorders Center), Wilma Barcellini(Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico), Oliver Andrés(University of Würzburg), Kevin H.M. Kuo(University Health Network), Rolandas Urbstonaitis(Agios Pharmaceuticals (United States)), Marta Morado(Hospital Universitario La Paz), Frederic Galactéros(Inserm), Vip Viprakasit(Siriraj Hospital), Andreas Glenthøj(University of Copenhagen), Bryan McGee(Agios Pharmaceuticals (United States)), Feng Tai(Agios Pharmaceuticals (United States)), D. Mark Layton(Imperial College Healthcare NHS Trust)
Cited by 2
Related Papers
Clinical heterogeneity and predictors of outcome in primary autoimmune hemolytic anemia: a GIMEMA study of 308 patients
|Blood|2014|373
A Phase 3 Trial of Luspatercept in Patients with Transfusion-Dependent β-Thalassemia
|New England Journal of Medicine|2020|320
Eltrombopag Added to Immunosuppression in Severe Aplastic Anemia
|New England Journal of Medicine|2022|309
Clinical Applications of Hemolytic Markers in the Differential Diagnosis and Management of Hemolytic Anemia
|Disease Markers|2015|281
Clinical Classification, Screening and Diagnosis for Thalassemia
|Hematology/Oncology Clinics of North America|2018|262